H.C. Wainwright raised the firm’s price target on Vertex Pharmaceuticals to $380 from $326 and keeps a Buy rating on the shares following the Q1 results. The analyst is focusing on VX-548’s Phase 2 program in the chronic pain setting. VX-548 needs to show over 35%-45% pain reduction on the Numeric Pain Rating Scale to be the best-in-class, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $384 from $342 at Barclays
- Vertex Pharmaceuticals reports Q1 EPS $2.69, consensus $3.00
- Vertex options imply 3.8% move in share price post-earnings
- VRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Vertex announces U.S. FDA approval for expanded use of Trikafta
